Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Low expression of PRRG2 in kidney renal clear cell carcinoma: an immune infiltration-associated prognostic biomarker. | Discov Oncol | 2024 | 38227081 | PubTator, text mining | PubMed |
| Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets. | Blood Sci | 2024 | 38226018 | PubTator, text mining | PubMed |
| LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior. | Aging (Albany NY) | 2024 | 38217544 | PubTator, text mining | PubMed |
| Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function. | Oncoimmunology | 2024 | 38192443 | PubTator, text mining | PubMed |
| Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities. | Cell Genom | 2024 | 38190106 | PubTator, text mining | PubMed |
| Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. | Cell Death Dis | 2024 | 38177102 | PubTator, text mining | PubMed |
| VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. | Cell Rep | 2024 | 38175754 | PubTator, text mining | PubMed |
| Systematic analysis of the prognostic value and immunological function of LTBR in human cancer. | Aging (Albany NY) | 2024 | 38175686 | PubTator, text mining | PubMed |
| [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. | Pathologie (Heidelb) | 2024 | 38170268 | PubTator, text mining | PubMed |
| Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers. | Int J Biol Sci | 2024 | 38169638 | PubTator, text mining | PubMed |
| Function and mechanism of GBP1 in the development and progression of cervical cancer. | J Transl Med | 2024 | 38167153 | PubTator, text mining | PubMed |
| Associations between HIFs and tumor immune checkpoints: mechanism and therapy. | Discov Oncol | 2024 | 38165484 | PubTator, text mining | PubMed |
| PD-1H/VISTA mediates immune evasion in acute myeloid leukemia. | J Clin Invest | 2024 | 38060328 | PubTator, text mining | PubMed |
| Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development. | Gene | 2024 | 38042220 | PubTator, text mining | PubMed |
| Genotyping and phylogeography of infectious bronchitis virus isolates from Pakistan show unique linkage to GI-24 lineage. | Poult Sci | 2024 | 37980750 | PubTator, text mining | PubMed |
| Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy. | Adv Sci (Weinh) | 2024 | 37934012 | PubTator, text mining | PubMed |
| B7-H3/CD276 and small-cell lung cancer: What's new? | Transl Oncol | 2024 | 37865049 | PubTator, text mining | PubMed |
| Activation of immune evasion machinery is a part of the process of malignant transformation of human cells. | Transl Oncol | 2024 | 37844478 | PubTator, text mining | PubMed |
| Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. | J Invest Dermatol | 2024 | 37562584 | PubTator, text mining | PubMed |
| Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response. | Curr Oncol | 2023 | 38275827 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=15